- This event has passed.
Approaches to Partnering with Pharma for AI Drug Discovery Companies
April 4, 2019 @ 4:30 pm - 8:00 pm
FreeBut what if we could automate the drug discovery process?
Large pharmaceutical companies are now using artificial intelligence (AI) to power their search for treatments. AI promises to make the drug discovery process easier, quicker, and cheaper. It is quickly becoming an invaluable tool for scientists both inside and outside big pharma. Specifically, scientists are using AI algorithms to search through large volumes of data to predict drug treatment results, identify diseases, and diagnose illnesses; enhancing insight, development and learning. Small companies are playing an increasingly important role in helping Big Pharma make AI a core part of their discovery engine.
On April 4th, Joseph Lehar, Vice President, Data Sciences, Oncology at Janssen Pharmaceutical Companies of Johnson & Johnson, will discuss how Janssen R&D is evolving their business model and partnering with AI companies to expedite drug discovery. You will also hear from 3 start-up companies with roots in Canada who are leveraging AI to exploit unique aspects of drug discovery. These companies will share their business model and how they are looking to partner with big pharma in the AI drug discovery space.
Keynote Speaker
Joseph leads a team responsible for creating unique and actionable medical insights using large and increasingly available datasets. Working in close collaboration with research scientists and other stakeholders, Joseph and his team apply data insights to inform decision-making, optimize innovation and identify best practices for applying data analytics in key areas of interest.
Joseph has global leadership responsibilities for a wide range of activities, including talent and capability development, training, resource deployment and supporting an organizational culture that promotes data-driven decision making across the Oncology Therapeutic Area, and together with partner teams.
Joseph holds a Ph.D. in physics and originally pursued a career in astrophysics at Massachusetts Institute of Technology (MIT), Cambridge University and Harvard University.